Cancer diagnostic startup Adela secures $60Mn in Series A funding

The company has entered into the market with a ground-breaking approach to detect cancer and other diseases

Disease diagnostic company, Adela has raised $60 million in a Series A funding round with aim to use this investment to develop a blood test that can detect cancer and other high-morbidity, high-mortality disorders by harnessing the potential of methylome.

Reportedly, F-Prime Capital headed the latest Series A funding round, with participation from Deerfield Management, OrbiMed, Decheng Capital, and RA Capital Management.

Sources claim that Adela's technology on genome-wide methylation can diagnose several disorders at scale with best results using a single assay.

As per Robert Weisskoff, Partner at F-Prime, Adela's technology, which uses next-generation methylation tech, offers a big leap in early cancer diagnosis and can provide an opportunity to save many lives.

DNA methylome contains a plethora of information about human disease, and methylation technologies have emerged as the primary tool for early detection of cancer and other diseases. Existing techniques, on the other hand, have been limited in their ability to thoroughly analyze the methylome for early signs of illness.

Adela's proprietary platform has the distinctive capacity to differentiate extremely insightful (methylated) portions of the genome from non-informative sections, allowing it to focus sequencing of those relevant regions.

The platform was developed by Daniel De Carvalho, Chief Scientific Officer, Adela, in collaboration with investigators at Sinai Health System. The firm’s technology can diagnose and identify underlying diseases with remarkable sensitivity and save as much genomic material as feasible by focusing on genome-wide relevant data regions.

Adela's technology is expected to be commercialized with the support of the recent Series A funding, with initial applications across cancer care ranging from early diagnosis to disease monitoring. The company intends to expand the use of the technology to cure other diseases in the future.

Source Credit -

By Shreya Bhute

With corporate exposure in software and marketing, Shreya was always intrigued by content development. Having pursued her graduation in I.T. engineering, she works as a content writer for and jots down news articles across distinct domains including technology, business and healthcare.